TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17513945

Group type: EXPERIMENTAL
Intervention: Diuretic therapy (hydrochlorothiazide 25 mg plus amiloride 5 mg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Diuretic therapy (hydrochlorothiazide plus amiloride)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Diuretic therapy
Number of subjects: 40
Study: 15551394

Group type: EXPERIMENTAL
Intervention: Solanum xanthocarpum and Solanum trilobatum (300 mg tds for 3 days)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Deriphylline (200 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Salbutamol (4 mg)
Number of subjects: 0
Study: 11435848

Group type: EXPERIMENTAL
Intervention: Transurethral prostatic resection
Number of subjects: 148

Group type: COMPARATOR
Intervention: Laser therapy (noncontact neodymium (Nd):YAG visual laser assisted prostatectomy)
Number of subjects: 148
Study: 9710355

Group type: EXPERIMENTAL
Intervention: Insulin lispro
Number of subjects: 7

Group type: COMPARATOR
Intervention: Regular human insulin
Number of subjects: 7
Study: 8041855

Group type: EXPERIMENTAL
Intervention: Monetary incentives for attendance
Number of subjects: 2006

Group type: COMPARATOR
Intervention: Nonmonetary incentives (food coupons or gift certificates)
Number of subjects: 2006
Study: 2920882

Group type: EXPERIMENTAL
Intervention: Midazolam (0.07 mg/kg)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Diazepam (0.15 mg/kg)
Number of subjects: 105
Study: 1147187

Group type: EXPERIMENTAL
Intervention: Pentobarbitone orally and morphine and hyoscine intramuscularly
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Diazepam 10 mg by mouth
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Diazepam 20 mg by mouth
Number of subjects: 4

Group type: COMPARATOR
Intervention: No premedication
Number of subjects: 4
Study: 31007226

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (20 μg) added to lignocaine bupivacaine peribulbar block
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group received lignocaine bupivacaine block
Number of subjects: 100
Study: 29845514

Group type: EXPERIMENTAL
Intervention: Behavioral group intervention
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Game (Kaledo) intervention
Number of subjects: 52

Group type: COMPARATOR
Intervention: Comparison between behavioral and game intervention groups
Number of subjects: 52
Study: 29798480

Group type: EXPERIMENTAL
Intervention: Bimodal group (CI + contralateral hearing aid)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Unilateral A group (only cochlear implant)
Number of subjects: 36
Study: 25072610

Group type: EXPERIMENTAL
Intervention: vRNA 51-200 copies per milliliter
Number of subjects: 833

Group type: EXPERIMENTAL
Intervention: Older age (≥45 vs. ≤30 years)
Number of subjects: 833

Group type: EXPERIMENTAL
Intervention: Hepatitis C virus antibody positivity
Number of subjects: 833

Group type: EXPERIMENTAL
Intervention: Hispanic vs. white
Number of subjects: 833

Group type: EXPERIMENTAL
Intervention: Lower concurrent CD4 count (≤200 vs. >500 cells/mm)
Number of subjects: 833

Group type: EXPERIMENTAL
Intervention: Lower concurrent CD4/CD8 ratio (per 0.5 unit increase)
Number of subjects: 833

Group type: EXPERIMENTAL
Intervention: Higher pre-ART CD8 T-cell activation (per 10% higher)
Number of subjects: 833
Study: 22067722

Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 60
Study: 19678919

Group type: EXPERIMENTAL
Intervention: Intensive renal replacement therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intermittent and continuous modalities of renal support
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Study therapy initiation and volume management
Number of subjects: 0
Study: 17497374

Group type: EXPERIMENTAL
Intervention: Knowledge of results feedback
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Kinetic feedback
Number of subjects: 60
Study: 16238892

Group type: EXPERIMENTAL
Intervention: Epoetin alfa
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: Epoetin alfa or Darbepoetin alfa
Number of subjects: 274
Study: 11874217

Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 829

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 829
Study: 9457283

Group type: EXPERIMENTAL
Intervention: Active treatment with the Dornier Urowave device
Number of subjects: 220

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 220
Study: 7631732

Group type: EXPERIMENTAL
Intervention: Progestin (500 micrograms of progestin derived from 19-norprogesterone, progestone)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 2718048

Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 0
Study: 124557

Group type: EXPERIMENTAL
Intervention: Tetracyclines
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clindamycin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Erythromycins
Number of subjects: 0
Study: 31615016

Group type: EXPERIMENTAL
Intervention: PGE571 (571 mg as PGE)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: PGE2855 (2855 mg as PGE)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study: 27427434

Group type: EXPERIMENTAL
Intervention: Mental simulation alone
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: Action planning alone
Number of subjects: 267

Group type: COMPARATOR
Intervention: Mental simulation and action planning strategies
Number of subjects: 267
Study: 25361650

Group type: EXPERIMENTAL
Intervention: 3D imaging system
Number of subjects: 122

Group type: COMPARATOR
Intervention: 2D imaging system
Number of subjects: 122
Study: 23222034

Group type: EXPERIMENTAL
Intervention: stepped combined care management, psychopharmacology, and cognitive behavioral psychotherapy intervention (n = 104)
Number of subjects: 207

Group type: COMPARATOR
Intervention: usual care control (n = 103)
Number of subjects: 207
Study: 21218311

Group type: EXPERIMENTAL
Intervention: Brief personalized motivational interventions
Number of subjects: 497

Group type: COMPARATOR
Intervention: Information and advice
Number of subjects: 497
Study: 18155052

Group type: EXPERIMENTAL
Intervention: Continuous lumbar plexus and sciatic nerve blocks (CPNB) with ropivacaine 0.2% for 48 hours
Number of subjects: 12

Group type: COMPARATOR
Intervention: Patient-controlled analgesia with morphine
Number of subjects: 12
Study: 17090995

Group type: EXPERIMENTAL
Intervention: Daily fluid intake measurement (1,035 ml average, SD=359 ml, range 210 ml to 2,050 ml)
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Caregiver's perceived barriers assessment
Number of subjects: 111
Study: 12910836

Group type: EXPERIMENTAL
Intervention: Endovascular approach with GDC‐10 coils
Number of subjects: 60

Group type: COMPARATOR
Intervention: Surgical clipping
Number of subjects: 60
Study: 10883747

Group type: EXPERIMENTAL
Intervention: Inhaled albuterol (180 microg four times daily for 7 days)
Number of subjects: 10
Study: 9008448

Group type: EXPERIMENTAL
Intervention: TNK-tissue plasminogen activator (TNK-TPA) administered as a single bolus over 5 to 10 seconds with doses ranging from 5 to 50 mg
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: TNK-tissue plasminogen activator (TNK-TPA)
Number of subjects: 113
Study: 8237804

Group type: EXPERIMENTAL
Intervention: Synchronized burst pacing
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Synchronized autodecremental (ramp) pacing
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (induced episodes)
Number of subjects: 21
Study: 4025160

Group type: EXPERIMENTAL
Intervention: Calcium channel blocker therapy (verapamil or nifedipine)
Number of subjects: 26
Study: 29722846

Group type: EXPERIMENTAL
Intervention: High-dose vitamin D3 (2 oral doses of 200,000 IU at 2 and 4 weeks)
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: High-dose vitamin D3
Number of subjects: 194
Study: 26769248

Group type: EXPERIMENTAL
Intervention: General practitioner‐led integrated diabetes care innovation
Number of subjects: 12
Study: 25675564

Group type: EXPERIMENTAL
Intervention: Sparrow-pecking moxibustion
Number of subjects: 90

Group type: COMPARATOR
Intervention: Acupuncture
Number of subjects: 90
Study: 23935398

Group type: EXPERIMENTAL
Intervention: Cilnidipine (10.27 ± 4.13 mg/day)
Number of subjects: 365

Group type: COMPARATOR
Intervention: Amlodipine (4.87 ± 2.08 mg/day)
Number of subjects: 365

Group type: EXPERIMENTAL
Intervention: Cilnidipine and Amlodipine
Number of subjects: 365
Study: 20868317

Group type: EXPERIMENTAL
Intervention: Self-directed exercise program provided by a qualified exercise professional, updated every 3 weeks for 12 weeks
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group maintained current lifestyle habits for 12 weeks
Number of subjects: 24
Study: 17983434

Group type: EXPERIMENTAL
Intervention: Oxybutynin transdermal system (OXY‐TDS) 3.9 mg/day
Number of subjects: 369
Study: 15725084

Group type: EXPERIMENTAL
Intervention: Standard dose melphalan-prednisone (MP)
Number of subjects: 272
Study: 12937332

Group type: EXPERIMENTAL
Intervention: Environmental Skill-Building Program (5 home contacts and 1 telephone contact by occupational therapists)
Number of subjects: 255

Group type: COMPARATOR
Intervention: Usual care control group
Number of subjects: 255
Study: 10733537

Group type: EXPERIMENTAL
Intervention: CLIP score
Number of subjects: 196

Group type: COMPARATOR
Intervention: Okuda staging system
Number of subjects: 196
Study: 9161271

Group type: EXPERIMENTAL
Intervention: Clearfil Liner Bond System
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: Scotchbond Multi‐Purpose
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: Experimental Bayer System 1
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: Experimental Bayer System 2
Number of subjects: 420
Study: 1382323

Group type: EXPERIMENTAL
Intervention: Iloprost (3000 ng infused into the graft)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 4052143

Group type: EXPERIMENTAL
Intervention: Flupirtine (3 X 100 mg on the previous day and 100 mg before the test)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Chlorphenoxamine (80 mg daily dose on the preceding day and 20 mg 1 h before test)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Diazepam (10 mg perorally 2 days before and 5 mg perorally on the preceding day)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 29265699

Group type: EXPERIMENTAL
Intervention: Indocyanine green administration 15 hours before surgery
Number of subjects: 72

Group type: COMPARATOR
Intervention: Indocyanine green administration at 3, 6, 9, 12, 15, 18, and 24 hours before surgery
Number of subjects: 72
Study: 26249333

Group type: EXPERIMENTAL
Intervention: Obesity prevention programs
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Implementation strategies for obesity prevention programs
Number of subjects: 41
Study: 24552831

Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 14236

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 14236
Study: 22339102

Group type: EXPERIMENTAL
Intervention: Acupuncture-like transcutaneous electrical nerve stimulation (AL-TENS) at Hegu (LI4) and Sanyinjiao (SP6) points, applied twice weekly for 8 weeks.
Number of subjects: 66

Group type: COMPARATOR
Intervention: AL-TENS on nonacupoints (Control group).
Number of subjects: 66
Study: 20166313

Group type: EXPERIMENTAL
Intervention: Short release time
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Long release time
Number of subjects: 24
Study: 18727133

Group type: EXPERIMENTAL
Intervention: Integrated mental health services in primary care
Number of subjects: 2022

Group type: COMPARATOR
Intervention: Referral to community-based services (Control)
Number of subjects: 2022
Study: 16207547

Group type: EXPERIMENTAL
Intervention: Pravastatin (group P)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Non-pravastatin (group NP)
Number of subjects: 34
Study: 12371079

Group type: EXPERIMENTAL
Intervention: L‐Thyroxin Henning 100
Number of subjects: 60

Group type: COMPARATOR
Intervention: Eferox 100
Number of subjects: 60
Study: 11064964

Group type: EXPERIMENTAL
Intervention: Group-based parent education programs
Number of subjects: 16

Group type: COMPARATOR
Intervention: Waiting list, no-treatment or placebo control group
Number of subjects: 16
Study: 9350101

Group type: EXPERIMENTAL
Intervention: Human leukocyte interferon-alpha cream (2 x 10(6) IU/g)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Human leukocyte interferon-alpha gel (2 x 10(6) IU/g)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 8457025

Group type: EXPERIMENTAL
Intervention: Terbutaline CR 10 mg twice daily
Number of subjects: 21

Group type: COMPARATOR
Intervention: Ipratropium 40 micrograms four times daily
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Combination of terbutaline CR and ipratropium
Number of subjects: 21
Study: 3092392

Group type: EXPERIMENTAL
Intervention: Glibenclamide and metformin
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Insulin treatment
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control group (no insulin treatment)
Number of subjects: 68
Study: 29700925

Group type: EXPERIMENTAL
Intervention: Punctal plug
Number of subjects: 48
Study: 27107842

Group type: EXPERIMENTAL
Intervention: Vegetarian diet without fish or meat
Number of subjects: 74

Group type: COMPARATOR
Intervention: Isocaloric conventional antidiabetic diet
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Combined groups
Number of subjects: 74
Study: 24643104

Group type: EXPERIMENTAL
Intervention: Epidural analgesia (Group 1)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Local infiltration analgesia (Group 2)
Number of subjects: 30
Study: 22572600

Group type: EXPERIMENTAL
Intervention: Wireless motility capsule (WMC)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Radioopaque markers (ROM)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Wireless motility capsule (WMC) and Radioopaque markers (ROM)
Number of subjects: 50
Study: 20533132

Group type: EXPERIMENTAL
Intervention: Perineal mesh rectopexy with sterile talc-soaked mesh
Number of subjects: 120

Group type: COMPARATOR
Intervention: Abdominal posterior mesh rectopexy
Number of subjects: 120
Study: 18664538

Group type: EXPERIMENTAL
Intervention: 20% lipid/heparin infusion
Number of subjects: 12

Group type: COMPARATOR
Intervention: saline/heparin infusion
Number of subjects: 12
Study: 15836682

Group type: EXPERIMENTAL
Intervention: Laterally directed epidural catheter (IUEC, n = 40)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Classic midline catheter (CMEC, n = 35)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Laterally directed epidural catheter (IUEC)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Classic midline catheter (CMEC)
Number of subjects: 75
Study: 12208800

Group type: EXPERIMENTAL
Intervention: Tranilast 450 mg BID for 3 months
Number of subjects: 11484

Group type: EXPERIMENTAL
Intervention: Tranilast (300 and 450 mg BID for 1 or 3 months)
Number of subjects: 11484

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11484
Study: 10335729

Group type: EXPERIMENTAL
Intervention: Rural teaching sites
Number of subjects: 294

Group type: COMPARATOR
Intervention: Urban and suburban teaching sites
Number of subjects: 294

Group type: COMPARATOR
Intervention: Primary care specialty (family medicine, medicine, pediatrics, joint medicine and pediatrics)
Number of subjects: 294

Group type: EXPERIMENTAL
Intervention: Geographic location of the site
Number of subjects: 294

Group type: COMPARATOR
Intervention: Primary care specialty and geographic location
Number of subjects: 294
Study: 8999380

Group type: EXPERIMENTAL
Intervention: Laser CO2 and intramuscular beta‐interferon
Number of subjects: 230

Group type: COMPARATOR
Intervention: Laser CO2
Number of subjects: 230
Study: 1958451

Group type: EXPERIMENTAL
Intervention: Nifedipine 10 mg three times daily with ranitidine 300 mg twice daily
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Nifedipine 10 mg three times daily with cimetidine 800 mg daily
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 31789723

Group type: EXPERIMENTAL
Intervention: Long-term medical therapy (up to 10 years)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Radioiodine ablation (RAI) with higher weight-based doses of I-131 (250 μCI/g thyroid tissue)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Maternal or neonatal TSH receptor antibodies and TSH at 3-7 days of age
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Long-term medical therapy beyond two years
Number of subjects: 0

Group type: COMPARATOR
Intervention: Radioiodine ablation (RAI)
Number of subjects: 0
Study: 31675546

Group type: EXPERIMENTAL
Intervention: Integrated MET/PE (n=95)
Number of subjects: 183

Group type: COMPARATOR
Intervention: Phased MET/PE (n=88)
Number of subjects: 183
Study: 28650680

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Finasteride, 5 mg per day for 4 weeks
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Dutasteride, 0.5 mg per day for 4 weeks
Number of subjects: 450
Study: 25037034

Group type: EXPERIMENTAL
Intervention: MF59-adjuvanted trivalent influenza vaccine (ATIV)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nonadjuvanted trivalent influenza vaccine (TIV)
Number of subjects: 0
Study: 24057811

Group type: EXPERIMENTAL
Intervention: Pregabalin + Dexamethasone
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Pregabalin + Placebo
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo + Placebo
Number of subjects: 60
Study: 21187264

Group type: EXPERIMENTAL
Intervention: High educational level
Number of subjects: 553

Group type: COMPARATOR
Intervention: Low educational level
Number of subjects: 553
Study: 19936182

Group type: EXPERIMENTAL
Intervention: Bilevel of 13-20 cmH(2)O
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Bilevel of 8-15 cmH(2)O
Number of subjects: 20
Study: 16904951

Group type: EXPERIMENTAL
Intervention: Additional communication strategy
Number of subjects: 167

Group type: COMPARATOR
Intervention: Usual communication strategy
Number of subjects: 167
Study: 14748901

Group type: EXPERIMENTAL
Intervention: Cholesterol-lowering drug treatment
Number of subjects: 0
Study: 11915781

Group type: EXPERIMENTAL
Intervention: Vitamin C supplementation (200 mg of ascorbic acid twice a day)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo (200 mg of lactose)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Vitamin C supplementation
Number of subjects: 16
Study: 9549449

Group type: EXPERIMENTAL
Intervention: Health education at birth and three months later (group A)
Number of subjects: 540

Group type: EXPERIMENTAL
Intervention: Health education at birth only (group B)
Number of subjects: 540

Group type: COMPARATOR
Intervention: No health education at birth (group C)
Number of subjects: 540

Group type: COMPARATOR
Intervention: No health education (group D)
Number of subjects: 540
Study: 8307445

Group type: EXPERIMENTAL
Intervention: Trospium chloride (15 mg orally thrice daily)
Number of subjects: 12
Study: 2661242

Group type: EXPERIMENTAL
Intervention: Sustained-release naproxen (1 g daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional naproxen capsules (500 mg twice daily)
Number of subjects: 0
Study: 1101907

Group type: EXPERIMENTAL
Intervention: Niflumic acid
Number of subjects: 0

Group type: COMPARATOR
Intervention: Aloxiprin
Number of subjects: 0
Study: 31025449

Group type: EXPERIMENTAL
Intervention: Pre-Frail Multicomponent Training Intervention (16-week training protocol, 60-min sessions, three alternate days, combining aerobic, muscle strength, flexibility, and balance exercises)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 28541500

Group type: EXPERIMENTAL
Intervention: Oral hyperimmune bovine IgG (bIgG) raised against CFA/I minor pilin subunit (CfaE)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Positive control (CFA/I fimbraie)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 25395392

Group type: EXPERIMENTAL
Intervention: Oral liposomal iron (30 mg/day)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Intravenous iron gluconate (1000 mg total, 125 mg infused weekly)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 99
Study: 23571819

Group type: EXPERIMENTAL
Intervention: Bifidobacterium animalis subsp. lactis BB-12 (daily dose of 10^10 colony-forming units)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Control group (xylitol or sorbitol tablets)
Number of subjects: 106
Study: 24800342

Group type: EXPERIMENTAL
Intervention: Monofilament, non-absorbable Polypropylene (Prolene) No. 1 suture material (Group-A)
Number of subjects: 274

Group type: COMPARATOR
Intervention: Polyfilament, absorbable, co-polymer of Polylactide with Polyglycolide (Vicryle) No. 1 (Group-B)
Number of subjects: 274
Study: 18995160

Group type: EXPERIMENTAL
Intervention: Placement on a gel pillow (n = 41)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Usual care on a standard mattress (n = 40)
Number of subjects: 81
Study: 16926566

Group type: EXPERIMENTAL
Intervention: Distributed practice regimen (weekly)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Massed practice regimen (1 day)
Number of subjects: 38
Study: 14510985

Group type: EXPERIMENTAL
Intervention: Streptococcal throat infections in psoriasis patients
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Beta-haemolytic streptococci culture from psoriasis patients
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Exacerbation of psoriasis after streptococcal isolation
Number of subjects: 208

Group type: COMPARATOR
Intervention: Control group (household controls)
Number of subjects: 208
Study: 10764030

Group type: EXPERIMENTAL
Intervention: Faecal specimens tested for pathogens
Number of subjects: 2803

Group type: EXPERIMENTAL
Intervention: Age comparison between individuals with and without pathogens
Number of subjects: 2803
Study: 8761842

Group type: EXPERIMENTAL
Intervention: Perindopril (n = 20)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (n = 10)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Perindopril
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Perindopril and Placebo
Number of subjects: 30
Study: 1307461

Group type: EXPERIMENTAL
Intervention: Diltiazem (180 to 240 mg daily, 3 to 4 tablets a day)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87